Prognostic biomarkers in endometrial and ovarian carcinoma (Q38185940)

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Markers for individualised therapy in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Contemporary management of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic parameters of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

The prognostic value of CD44 isoform expression in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Lipocalin 2 expression is associated with aggressive features of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Overexpression of Wnt7a is associated with tumor progression and unfavorable prognosis in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Molecular classification of human endometrial cancer based on gene expression profiles from specialized microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Identification of a gene expression signature for survival prediction in type I endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

MicroRNA signatures differentiate uterine cancer tumor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic significance of miR-205 in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Resistance to chemotherapy and hormone therapy in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Targeted therapies in gynecologic cancers and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

"Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Value of PAX 8 immunostaining in tumor diagnosis: a review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

WT1 expression in the female genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms: Table 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Pathology of primary and metastatic mucinous ovarian neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

The prognostic significance of elongation factor eEF1A2 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

A seven-gene prognostic model for platinum-treated ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1509-Y

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients

21 January 2018

1 reference

12 December 2020

Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma

1 reference

12 December 2020

Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer

1 reference

12 December 2020

VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer

1 reference

12 December 2020

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

1 reference

12 December 2020

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

1 reference

12 December 2020

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma

1 reference

12 December 2020

Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III-IV serous ovarian carcinoma

1 reference

12 December 2020

Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type

1 reference

12 December 2020

Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer

1 reference

12 December 2020

1 reference

12 December 2020

Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas

1 reference

12 December 2020

Targeting tyrosine-kinases in ovarian cancer

1 reference

12 December 2020

PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy

1 reference

12 December 2020

MicroRNA and endometrial cancer: Roles of small RNAs in human tumors and clinical applications (Review).

1 reference

12 December 2020

DNA ploidy in endometrial carcinoma: major objective prognostic factor

1 reference

12 December 2020

Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer

1 reference

12 December 2020

Use of mutation profiles to refine the classification of endometrial carcinomas.

1 reference

12 December 2020

Defective mismatch repair and the development of recurrent endometrial carcinoma

1 reference

12 December 2020

Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis.

1 reference

12 December 2020

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

1 reference

12 December 2020

Prognostic significance of p53 overexpression in endometrial cancer

1 reference

12 December 2020

The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer

1 reference

12 December 2020

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient

1 reference

12 December 2020

HER-2/neu expression: a major prognostic factor in endometrial cancer

1 reference

12 December 2020

HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas

1 reference

12 December 2020

CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker

1 reference

12 December 2020

Visfatin, a potential biomarker and prognostic factor for endometrial cancer

1 reference

12 December 2020

Five year survival rate in endometrial carcinoma stages I--II: influence of degree of tumour differentiation, age, myometrial invasion and DNA content

1 reference

12 December 2020

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype

1 reference

12 December 2020

GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival

1 reference

12 December 2020

Prognostic significance of a novel proliferation marker, anti-repp 86, for endometrial carcinoma: a multivariate study

1 reference

12 December 2020

Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial

1 reference

12 December 2020

Histologic subtypes of ovarian carcinoma: an overview.

1 reference

12 December 2020

Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis

1 reference

12 December 2020

Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma

1 reference

12 December 2020

Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis

1 reference

12 December 2020

Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma

1 reference

12 December 2020

Immunohistochemical assessment of p170 provides prognostic information in endometrial carcinoma

1 reference

12 December 2020

Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival

1 reference

12 December 2020

Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters

1 reference

12 December 2020

Amplification of 11q13 in ovarian carcinoma

1 reference

12 December 2020

Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas

1 reference

12 December 2020